Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026
2027
2028
2029
2030
Trend
ROE
-148.35%
-860.61%
117.8%
59.86%
40.94%
30.63%
ROA
-95.88%
-93.46%
-113.01%
-125.44%
-134.75%
-139.59%
Gross Margin
100%
100%
100%
100%
100%
100%
Sector average
16.85%
17.71%
17.71%
17.71%
17.71%
17.71%
Total Assets
SEK 50,862.00K
SEK 41,276.65K
SEK 42,550.71K
SEK 44,461.41K
SEK 46,042.88K
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for Prostatype Genomics AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
SEK 46,947.81K
Sector average
SEK 2,857,190.78K
SEK 2,900,240.60K
SEK 3,045,009.79K
SEK 3,280,286.42K
SEK 3,536,407.14K
SEK 3,762,908.71K
Net Income
-SEK 44,503.00K
-SEK 43,054.46K
-SEK 47,365.07K
-SEK 54,574.58K
-SEK 60,978.34K
-SEK 64,900.67K
Sector average
-SEK 2,851.32K
-SEK 22,027.28K
-SEK 904.69K
-SEK 7,253.84K
-SEK 3,858.45K
-SEK 1,547.00K
Valuation
SEK 168,027.45K
SEK 162,558.29K
SEK 178,833.62K
SEK 206,054.13K
SEK 230,232.46K
SEK 245,041.79K
Sector average
SEK 3,960,502.41K
SEK 5,151,301.60K
SEK 5,189,236.02K
SEK 5,317,343.69K
SEK 5,514,329.75K
SEK 5,636,782.17K
Stock Price
SEK 0.30
SEK 0.29
SEK 0.32
SEK 0.37
SEK 0.41
SEK 0.44
Sector average
SEK 57.22
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
Prostatype Genomics AB (publ) (PROGEN.ST) Financial Forecast | Equlion
